Saturday, 23 May 2026 12:05 PM
Advertorial
A verification-first review of the $99.95 four-ingredient synbiotic formula, the 100-day guarantee, the WADA classification competitive athletes must factor in, and what the evolving regulatory landscape means for BPC-157 supplement buyers in 2026.
CARPINTERIA, CA / ACCESS Newswire / May 23, 2026 / This article contains affiliate links. A commission may be earned on qualifying purchases made through links in this content, at no additional cost to the reader. Affiliate relationships do not influence editorial content or the evaluation of products. Disclosure is provided in accordance with FTC 16 CFR Part 255. The statements in this article have not been evaluated by the Food and Drug Administration. Products discussed are not intended to diagnose, treat, cure, or prevent any disease. BPC-157 is not FDA-approved for any human therapeutic use. Information provided is for general informational purposes and does not constitute medical advice. Readers experiencing symptoms or considering changes to health regimens should consult a licensed healthcare professional. Individual results vary. Always confirm current pricing, availability, and terms on the official brand website before purchasing.
Last Updated: May 2026 - pricing, label specifications (REV.04.25), and regulatory status verified at publication.
ProHealth Longevity BPC-157 Ultra Probiotic Review (2026): What the Label Actually Discloses and What Buyers Should Verify First
What could be verified, what could not, and what buyers should check before the BPC-157 regulatory landscape evolves further.
WHAT THIS ARTICLE VERIFIED: The evaluation in this article is based on the official ProHealth product page at prohealth.com, the physical Supplement Facts label (REV.04.25), the brand's published FAQ and company background materials, published research cited on the product page, FDA and WADA regulatory documentation publicly available as of May 2026, and a review of competing wire releases in the BPC-157 supplement category. No unpublished data, insider access, or brand-provided samples informed this review. Where source data could not be verified, the gap is documented rather than filled with assumption.
TL;DR: ProHealth Longevity BPC-157 Ultra Probiotic is a synbiotic supplement combining 500mcg BPC-157 Arginine Salt with MicrobiomeX® prebiotic, Clostridium butyricum probiotic, and ButyroGen® tributyrin postbiotic - priced at $99.95 for 30 servings. According to the company, the formula is designed around butyrate-related digestive support mechanisms. BPC-157's proposed mechanisms are based on pre-clinical animal research only; no human RCTs have established efficacy. ProHealth discloses full Supplement Facts (no proprietary blends), publishes triple third-party lab Certificates of Analysis, and backs the formula with a 100-day return window - all verifiable at prohealth.com. BPC-157 is not FDA-approved for human therapeutic use.
Is ProHealth BPC-157 Ultra Probiotic worth buying? For buyers seeking a synbiotic formula with full label transparency, triple third-party lab testing, and a 100-day return window, the product offers verifiable disclosures uncommon in the peptide category. It is not appropriate for buyers expecting FDA-approved outcomes, competitive athletes subject to WADA testing, or anyone seeking treatment for a medical condition.
Quick Verdict: What Can and Cannot Be Verified About This Formula
Most supplement reviews for products in this category lead with claims and end with fine print. This one inverts that structure - because with a research-stage peptide like BPC-157 combined with a functional synbiotic system, what the brand discloses and what the science actually supports are two different conversations that deserve to be separated cleanly.
What can be verified about ProHealth's BPC-157 Ultra Probiotic:
The Supplement Facts label (REV.04.25) discloses all four active ingredients and their exact per-serving amounts with no proprietary blends.
The formula uses BPC-157 as the Arginine Salt form, which ProHealth states offers greater stability in the gastrointestinal environment than acetate forms commonly found in other products.
MicrobiomeX® and ButyroGen® are registered trademarked ingredients with published clinical data - their mechanisms are documentable at the ingredient level.
ProHealth states each batch is independently tested three times by third-party labs with Certificates of Analysis published on the product page.
The company has operated since 1988 and carries an A+ Better Business Bureau rating per publicly available records.
The 100-day money-back guarantee terms are stated on the product page.
What honest evaluation requires acknowledging:
BPC-157 has no FDA-approved human therapeutic application. Pre-clinical research conducted primarily in animal models informs the hypotheses for its use, but no large randomized controlled trials in humans have confirmed efficacy for any outcome - including gut-lining support, tissue-related processes, or any other claimed mechanism.
BPC-157 is classified by WADA in the S0 Unapproved Substances category, meaning it is prohibited in professional and competitive sport regardless of administration route.
The 500mcg oral dose in this formula is substantially lower than the doses used in pre-clinical injectable research. The clinical translation of those findings to an oral supplement context has not been established through published human pharmacokinetic data.
Why the timing of this purchase decision matters: BPC-157's regulatory landscape is evolving. FDA has raised regulatory and safety concerns regarding certain BPC-157-related bulk substances used in compounding contexts, and the dietary supplement classification of BPC-157 products has been a topic of industry discussion through 2025 and into 2026. None of this means a buyer should rush a purchasing decision - but it does mean that the product as currently formulated, priced, and available may not remain in its current form indefinitely. The 100-day return window and current $99.95 pricing reflect today's market; buyers evaluating this product should factor regulatory volatility into their decision timeline rather than assuming indefinite availability. Readers comparing options within this category may benefit from broader category analysis covering verified oral BPC-157 formulations before finalizing their decision.
Both categories of information matter. Reviewing both may help buyers make a more informed purchasing decision.
Affiliate disclosure: A commission may be earned on purchases made through links in this article at no additional cost to the reader, per FTC 16 CFR Part 255.
What Is BPC-157 Ultra Probiotic? Understanding the Synbiotic Architecture
ProHealth's BPC-157 Ultra Probiotic is not a standard probiotic with a peptide added for marketing appeal. According to the company, the formula was designed around a specific functional objective: formulated around butyrate-related digestive support mechanisms delivered through multiple simultaneous pathways - direct delivery, bacterial production, and microbiome prebiotic support.
The brand describes this as a "synbiotic" approach, which in supplement science terminology refers to a combination of prebiotics and probiotics working in coordination. ProHealth extends this architecture by adding both a postbiotic (directly delivered butyrate via ButyroGen®) and a peptide (BPC-157) that pre-clinical animal research suggests may support the gastrointestinal environment - a mechanism the brand describes based on its own published references, not as an established human clinical outcome.
Per the company's published materials, the logic of the formula runs as follows: butyrate is the preferred fuel source for colonocytes (the cells lining the colon). According to the brand, it supports the intestinal environment, promotes a balanced microbiome, and plays a role in gut-brain signaling pathways - claims the company makes based on its cited ingredient-level research. Many adults do not produce sufficient butyrate due to diets low in the specific fibers and polyphenols that butyrate-producing bacteria require. The formula addresses this from four angles simultaneously: providing BPC-157 to support the GI environment, feeding butyrate-producing microbes with MicrobiomeX® prebiotic, supplying a butyrate-producing bacterial strain directly (Clostridium butyricum), and delivering preformed butyrate to the colon via ButyroGen® tributyrin.
This architecture is documentable from the company's published ingredient disclosures. Whether it produces the described outcomes in individual consumers is subject to the individual results variability that applies to all dietary supplements. These statements describe ingredient-level structure/function mechanisms and have not been evaluated by the Food and Drug Administration.
Supplement Facts: What the Label Discloses Per Serving
The verified Supplement Facts panel (REV.04.25) discloses the following per two-capsule serving (30 servings per container):
MicrobiomeX® Prebiotic (from Orange and Grapefruit Fruit Extracts): 500mg
ButyroGen® Tributyrin Complex: 200mg
Clostridium butyricum (1 Billion CFU): 100mg
Body Protection Compound-157 (as BPC-157 Arginine Salt): 500mcg
Daily Value not established for all four ingredients. Other ingredients: vegetable cellulose (capsule), acacia fiber, guar fiber, rosemary extract, microcrystalline cellulose, silica. The capsule is vegetable cellulose, confirming vegan-friendly formulation per the brand.
Transparency Note: No proprietary blends appear in this formula. Every active ingredient is disclosed with its exact per-serving amount. This level of label transparency is not standard in the current peptide supplement market, where blends often obscure individual dosages.
The BPC-157 dose warrants specific context: 500mcg (0.5mg) per serving is the disclosed oral dose. Pre-clinical research on BPC-157 has used various administration routes and dose ranges, often in injectable form. The oral bioavailability of BPC-157 as an Arginine Salt, and how a 500mcg oral dose compares to amounts studied in animal models, represents an open question that published human pharmacokinetic data has not yet resolved. ProHealth addresses this in their product FAQ, stating that BPC-157's natural presence in gastric juice gives it gastric stability that supports oral absorption - but published human pharmacokinetic data for this exact finished product and dose could not be verified in the peer-reviewed literature reviewed for this article.
Ingredient-Level Evidence: What the Research Actually Says
Each ingredient in the formula carries a distinct evidence profile. The following summarizes what published research supports at the ingredient level, attributed as such - not as evidence of whole-product outcomes.
BPC-157 (Body Protection Compound-157, Arginine Salt Form)
BPC-157 is a 15-amino acid synthetic peptide derived from a protective protein found naturally in human gastric juice. According to the company and consistent with published pre-clinical literature, it has been studied in animal models for pre-clinical signals related to the gastrointestinal environment, inflammatory responses in the GI tract, and tissue-related processes in tendon and joint contexts - all per pre-clinical animal data, not established human clinical outcomes.
Published pre-clinical citations on the product page include research by Sikiric et al. (J Physiol Paris, 2001; Pharm Basel Switz, 2023), Vukojevic et al. (Neural Regen Res, 2022), Cushman et al. (Yale J Biol Med, 2024), Gwyer et al. (Cell Tissue Res, 2019), and Klicek et al. (J Physiol Pharmacol, 2013), among others. These are animal model studies. A 2025 systematic review published in HSS Journal (Vasireddi et al.) reviewing BPC-157's use in orthopaedic sports medicine noted that preclinical data shows potential in musculoskeletal injuries but that human randomized controlled trial data remains absent. For readers tracking how brand-stated mechanisms in this category align with verifiable evidence, earlier analysis of BPC-157 supplement claims and ingredient transparency standards provides additional context.
Buyer Note: BPC-157 is currently classified under WADA's S0 category (Unapproved Substances) and is prohibited in competitive sport. It is not a DEA-scheduled substance. However, BPC-157's regulatory status is complex and may vary by use, jurisdiction, and product category - including FDA regulatory and safety concerns regarding certain BPC-157-related bulk substances used in compounding contexts. Buyers should verify current rules in their jurisdiction and applicable testing programs before purchase.
MicrobiomeX® Prebiotic (500mg)
MicrobiomeX® is a patented citrus polyphenol extract (from orange and grapefruit fruit) developed by BioActor B.V. The brand's published materials reference a clinical study (Sost MM et al., Nutrients, 2021) showing that MicrobiomeX® intake was associated with shifts in the microbiome toward butyrate-producing bacterial populations. At the ingredient level, this is a documented mechanism - the compound acts on the microbial composition rather than delivering butyrate directly.
ButyroGen® Tributyrin Complex (200mg)
ButyroGen® is a registered trademark of NutriScience Innovations, LLC. Tributyrin is a triglyceride form of butyric acid that the company describes as a more targeted delivery mechanism for butyrate than sodium butyrate, which is known for its odor and may be partially absorbed before reaching the colon. The brand references a clinical study (Dosz E et al., Nutraceuticals, 2025) showing a 26.4% improvement in digestive comfort associated with ButyroGen® at the ingredient level. This result is attributed to the cited ingredient-level study and does not represent a whole-product outcome claim.
Clostridium butyricum (1 Billion CFU)
Clostridium butyricum is a spore-forming probiotic strain with documented use in clinical and commercial settings, particularly in Asian and European markets. As a spore-former, it is inherently shelf-stable and designed to survive gastric acid transit. Published research (Stoeva MK et al., Gut Microbes, 2021) on Clostridium butyricum confirms it is a direct butyrate-producing organism in the gut. The 1 Billion CFU per serving is the disclosed dose - no comparison to other probiotic CFU counts should be inferred without consultation of individual product Supplement Facts.
Is ProHealth a Legitimate Company? Verifiable Background Indicators
Legitimacy in the supplement industry is primarily a function of verifiable operating history, quality claims that can be independently checked, and accessible customer support infrastructure. The following are documentable from publicly available sources.
ProHealth, Inc. has operated since 1988 - over 36 years as of 2026. The company is headquartered at 1025 Cindy Lane, Carpinteria, CA 93013. Contact is available via [email protected] and through the customer service infrastructure described on the brand's website. The company carries an A+ Better Business Bureau rating per publicly available records.
ProHealth states that all products are manufactured in the USA in facilities subject to FDA dietary supplement current Good Manufacturing Practice (cGMP) requirements under 21 CFR Part 111. The company describes its facilities as GMP-certified per its published materials. The company publishes Certificates of Analysis for its BPC-157 products, which it states are tested three times by independent third-party labs for identity, purity, potency, and contaminants including heavy metals, microbial pathogens, residual solvents, and LPS (lipopolysaccharide) contamination. The Certificates of Analysis for BPC-157 Ultra Probiotic are linked from the product page.
The product is available through prohealth.com and authorized third-party retailers including iHerb and Target. Pricing is subject to MAP enforcement at $99.95 per the product page and retailer listings reviewed. Readers researching brand track record may also find value in previous reporting examining customer experience patterns with this brand.
Check current ProHealth BPC-157 Ultra Probiotic stock and pricing through this promotional link
Pricing, Guarantee, and Purchasing Details
Per the official ProHealth website reviewed for this article, BPC-157 Ultra Probiotic - 60 capsules (30-day supply at the recommended two-capsule daily dose) - is priced at $99.95 for a one-time purchase. Pricing is subject to change; confirm current pricing at prohealth.com before purchasing. Official brand website: prohealth.com
ProHealth offers a Subscribe and Save program on select products, though availability for this specific SKU should be confirmed at checkout. New newsletter subscribers may receive a coupon for 20% off a first order per the brand's stated promotional policy, applicable to new customers and subscribers only, and excluding certain product types.
The brand's stated return policy is a 100-day money-back guarantee. Per the company's published return terms, customers not fully satisfied may contact the Santa Barbara, CA office for a full refund. Contact for returns is available through the brand's website at prohealth.com. Return terms are subject to change; the brand's current policy page is the authoritative source.
Free standard shipping on U.S. orders over $30 is stated on the product page.
Who Is This Product Suited For? A Self-Assessment Framework
Rather than making outcome claims, the most useful framing for a research-stage category is a self-qualification exercise. The following reflects the brand's stated target use case combined with the compliance context established above.
ProHealth's BPC-157 Ultra Probiotic is described by the company as designed for adults seeking advanced support for digestive health, particularly those who have not experienced satisfactory results with standard probiotic supplementation. The formula's architecture - combining a peptide with a pre/pro/postbiotic system - is positioned for individuals interested in a multi-mechanism gut support approach.
This product may align with people who:
Have used standard single-strain probiotics without meaningful digestive improvement and want to explore a more comprehensive synbiotic approach.
Are in the longevity and biohacking community familiar with research-stage compounds and who understand the preclinical-only evidence base for BPC-157.
Want full ingredient transparency, third-party lab verification, and a substantive return window before committing to a 30-day supply.
Are interested specifically in butyrate-focused gut support and want to understand the mechanisms behind a formula before purchasing.
This product is not appropriate for:
Anyone seeking an FDA-approved treatment for a digestive condition. BPC-157 is not FDA-approved for any human therapeutic use.
Competitive athletes subject to WADA testing or other drug testing programs, as BPC-157 is classified as a prohibited substance under WADA's S0 category.
Individuals under 18, pregnant or nursing individuals, or those with active medical conditions - per the brand's own label caution, physician consultation is recommended before use in these groups.
Review Methodology and Evidence Standards Applied
The evaluation in this article is based on the following sources: the official ProHealth product page at prohealth.com, the Supplement Facts label as published (REV.04.25), the brand's published FAQ and company background materials, published research cited on the product page, and publicly available scientific literature on BPC-157's regulatory and research status. No unpublished data, insider access, or brand-provided samples informed this review. Ingredient-level citations are attributed to the ingredient - not used as proxies for whole-product outcome claims.
Last Updated: May 2026
Frequently Asked Questions
Is ProHealth Longevity BPC-157 Ultra Probiotic the same as ProHealth's Pure BPC-157 product?
No, these are two separate SKUs. ProHealth's Pure BPC-157 is a single-ingredient product delivering 500mcg of BPC-157 per capsule. BPC-157 Ultra Probiotic is a synbiotic formula that combines the same 500mcg BPC-157 Arginine Salt dose with three additional gut-support ingredients: MicrobiomeX® prebiotic (500mg), ButyroGen® tributyrin postbiotic (200mg), and Clostridium butyricum probiotic (1 Billion CFU). The Ultra Probiotic is specifically designed around the butyrate production mechanism, making it a distinct product category from the single-peptide offering. Buyers interested specifically in the gut synbiotic architecture should evaluate the Ultra Probiotic; those focused solely on the peptide may find the Pure BPC-157 relevant instead.
What is BPC-157, and is it safe to take orally?
BPC-157 (Body Protection Compound-157) is a 15-amino acid synthetic peptide derived from a naturally occurring protective protein found in human gastric juice. Pre-clinical research conducted primarily in animal models has studied its potential roles in supporting the GI environment, gut barrier function, and inflammatory responses in the GI tract. ProHealth states that unlike many peptides requiring injection, BPC-157's natural presence in the gastric environment gives it stability for oral delivery - and the company's formula uses the Arginine Salt form to support oral bioavailability. The brand's FAQ states that BPC-157 is "considered safe when used as directed" based on preclinical trial data showing no significant side effects at recommended dosages - that is the company's characterization, attributed here as such. Human safety and efficacy data from large randomized controlled trials does not exist for this compound. BPC-157 has no FDA-approved human therapeutic application, and published human pharmacokinetic data for this exact finished product and dose could not be verified in the peer-reviewed literature reviewed for this article. Consultation with a healthcare professional before use is strongly recommended.
What is butyrate and why does this formula focus on it?
Butyrate is a short-chain fatty acid that functions as the primary fuel source for colonocytes - the cells lining the colon. According to ProHealth's published materials and published nutritional science, butyrate is described as playing roles in supporting the intestinal environment, promoting a balanced microbiome, regulating colonic pH, and contributing to gut-brain communication pathways - mechanisms supported by nutritional research at the ingredient level. The company's formula targets butyrate from three directions simultaneously: MicrobiomeX® feeds butyrate-producing bacteria, Clostridium butyricum directly produces butyrate in the intestines, and ButyroGen® tributyrin delivers preformed butyrate directly to the colon. BPC-157 is included as a GI environment support peptide that per pre-clinical animal data may help support the digestive environment in which these mechanisms operate, according to the brand's published materials. The butyrate-centered framework is the architectural logic behind the synbiotic classification of this product.
What is MicrobiomeX® and who makes it?
MicrobiomeX® is a patented citrus polyphenol prebiotic ingredient derived from orange and grapefruit fruit extracts. It is a registered trademark of BioActor B.V., a Dutch ingredient company. According to ProHealth's cited reference (Sost MM et al., Nutrients, 2021), MicrobiomeX® has been studied in clinical settings for its effect on shifting the gut microbiome toward butyrate-producing bacterial populations. It is included in BPC-157 Ultra Probiotic at 500mg per serving - the highest dose ingredient in the formula by weight. As a prebiotic, its function is to selectively feed beneficial bacteria rather than directly introducing organisms.
What is ButyroGen® and how does it differ from regular butyrate supplements?
ButyroGen® is a registered trademark of NutriScience Innovations, LLC for their tributyrin complex. Tributyrin is a triglyceride (fat) form of butyric acid, which the company and published material suggest may be more targeted in delivery than sodium butyrate - a more common but odorous and potentially less colon-specific butyrate supplement form. ProHealth's cited clinical study (Dosz E et al., Nutraceuticals, 2025) reported a 26.4% improvement in digestive comfort associated with ButyroGen® at the ingredient level. That result is attributed to the ingredient-level study and does not represent a whole-product outcome claim for BPC-157 Ultra Probiotic. ButyroGen® appears in the formula at 200mg per serving as the direct butyrate delivery mechanism.
Is Clostridium butyricum a safe probiotic strain?
Clostridium butyricum has a documented history of use as a probiotic, particularly in Asian and European markets where it has been commercially available for decades. ProHealth's product FAQ characterizes it as a well-researched strain with a long safety record. As a spore-forming organism, it is shelf-stable without refrigeration and is designed to survive gastric acid, activating in the intestines where it produces butyrate. Published research (Stoeva MK et al., Gut Microbes, 2021) documents its butyrate-producing function. The brand includes it at 1 Billion CFU per serving. As with any probiotic, individuals with compromised immune systems or specific health conditions should consult a healthcare professional before use.
Does ProHealth test its BPC-157 for purity and contamination?
According to ProHealth's published quality disclosures, each batch of BPC-157 products undergoes independent third-party testing three times - covering identity, purity, and potency, as well as contaminants including heavy metals, microbial pathogens, residual solvents, and LPS (lipopolysaccharide) contamination. Certificates of Analysis are published on the product page at prohealth.com for buyer review. LPS testing is specifically noted on the brand's FAQ page for the BPC-157 product line, which is a relevant quality marker given that LPS contamination can cause inflammatory responses. Independently verifying certificates by downloading them directly from the brand's site is the recommended approach for buyers who want to confirm testing claims.
Is BPC-157 banned in sports or subject to drug testing?
Yes. BPC-157 is classified under the World Anti-Doping Agency (WADA) S0 category - Unapproved Substances - and is prohibited in competitive sport regardless of the route of administration. This classification applies to professional athletes and those subject to WADA-compliant drug testing programs. BPC-157 is not a DEA-scheduled substance. However, its broader regulatory status is complex - FDA has raised regulatory and safety concerns regarding certain BPC-157-related bulk substances used in compounding contexts, and classifications may vary by use, jurisdiction, and product category. Any buyer subject to drug testing - whether in professional sport, military service, or other testing programs - should verify the compound's current status under the applicable testing code before purchasing or using any BPC-157 product. Buyers should also confirm current U.S. regulatory status independently before purchase.
Is BPC-157 being banned or pulled from the market?
As of May 2026, BPC-157 dietary supplements remain available for purchase in the United States. However, the regulatory landscape is evolving. FDA has raised regulatory and safety concerns regarding certain BPC-157-related bulk substances used in compounding contexts, and FDA has historically taken enforcement action against compounded BPC-157 preparations marketed for therapeutic injection. The dietary supplement category - where ProHealth's BPC-157 Ultra Probiotic is positioned - operates under different regulatory authority than compounded preparations, but classifications may evolve. No FDA action has been publicly announced as of this writing that would remove dietary supplement BPC-157 products from the market. However, buyers and prospective buyers should monitor FDA announcements and the brand's communications for any future regulatory changes. The 2026 WADA Prohibited List, which classifies BPC-157 in the S0 Unapproved Substances category, applies to competitive sport contexts and is separate from FDA dietary supplement oversight.
Will BPC-157 supplements stay on the market long-term?
Long-term availability of any dietary supplement category subject to ongoing regulatory review cannot be guaranteed. BPC-157 has been a subject of FDA attention in compounded pharmaceutical contexts, and dietary supplement classifications can change. ProHealth has continued to manufacture and distribute the product as of May 2026, and the brand has operated in the supplement industry since 1988 - a track record that reflects experience navigating regulatory environments. However, no responsible party can predict the long-term regulatory trajectory of BPC-157 in dietary supplement form. Buyers prioritizing access to this specific formulation should factor regulatory uncertainty into their purchase timing rather than assume the current product, pricing, and availability will persist indefinitely. The brand's 100-day return window provides a defined evaluation period regardless of broader market conditions.
What is ProHealth's return policy for BPC-157 Ultra Probiotic?
Per ProHealth's published guarantee terms, the company offers a 100-day money-back guarantee on its products. Customers who are not fully satisfied may contact the company's Santa Barbara, CA office for a full refund. Return terms and conditions are published at prohealth.com, which is the authoritative and current source for return policy details. Official brand website: prohealth.com Terms are subject to change; confirm current return terms before purchase. The company's general customer service contact is [email protected].
How does ProHealth's BPC-157 compare to injectable BPC-157 protocols?
This is one of the most common questions in the BPC-157 supplement category and deserves a direct answer. Injectable BPC-157 used in pre-clinical animal research and in off-label clinical settings typically involves higher doses and subcutaneous or intraperitoneal administration. ProHealth's oral capsule format uses a 500mcg dose of BPC-157 Arginine Salt per serving. The company's rationale for oral delivery is based on BPC-157's natural presence in gastric juice, which suggests inherent gastric stability. The Arginine Salt form is described by the company as supporting oral bioavailability. However, published human pharmacokinetic data comparing oral to injectable absorption at equivalent doses has not been established in peer-reviewed literature. Buyers considering BPC-157 should understand that the oral supplement form is categorically different from clinical injectable protocols, and that outcome comparisons between the two routes should not be assumed. Readers conducting deeper due diligence on this product family may find comprehensive prior coverage on what buyers should review before purchasing peptide supplements useful for cross-reference.
Where is ProHealth BPC-157 Ultra Probiotic manufactured?
According to ProHealth's published company information, all products are manufactured in the United States in facilities subject to FDA dietary supplement current Good Manufacturing Practice (cGMP) requirements under 21 CFR Part 111. ProHealth describes its facilities as GMP-certified in its published materials. The company is headquartered at 1025 Cindy Lane, Carpinteria, CA 93013. ProHealth states it has maintained this domestic manufacturing commitment since its founding in 1988. FDA cGMP requirements for dietary supplements under 21 CFR Part 111 cover cleanliness, process controls, equipment maintenance, and quality system requirements. Meeting cGMP standards does not constitute FDA approval of the product itself, and FDA does not pre-approve dietary supplements before sale.
Email: [email protected]
Toll Free: (800) 366-6056
USA: (805) 564-3064
INT: 001.805.564.3064
USA Fax: (805) 684-6199
INT Fax: 001.805.684-6199
Pharmaceuticals Customer Support: (800)366-5924
Product Return Address: ProHealth, Inc. 1025 Cindy Lane Carpinteria, CA 93013 USA
FDA DISCLAIMER: The statements in this article have not been evaluated by the Food and Drug Administration. Products discussed are not intended to diagnose, treat, cure, or prevent any disease. BPC-157 is not FDA-approved for any human therapeutic use, and this article does not claim that ProHealth BPC-157 Ultra Probiotic diagnoses, treats, cures, or prevents any disease. Dietary supplements are regulated differently than pharmaceutical drugs under FDA oversight. FDA does not pre-approve dietary supplements before they are sold. The information in this article is for general informational purposes only and does not constitute medical or pharmaceutical advice.
FTC AFFILIATE DISCLOSURE: This article contains affiliate links. A commission may be earned on qualifying purchases made through links in this content, at no additional cost to the reader. The existence of an affiliate relationship does not influence the factual accuracy, completeness, or editorial integrity of the content presented. Disclosure is made in accordance with FTC 16 CFR Part 255 guidelines governing endorsements and testimonials in advertising.
RESULTS VARIABILITY DISCLAIMER: Individual results from dietary supplement use vary based on numerous factors including age, health status, diet, exercise, and other variables. No specific outcomes are guaranteed. Results described in customer reviews reflect individual experiences and are not representative of typical results. The brand-reported customer reviews cited on this page reflect experiences submitted to the company and have not been independently verified.
MEDICAL ADVICE DISCLAIMER: Nothing in this article constitutes medical advice. Readers with health conditions, those taking prescription medications, pregnant or nursing individuals, and individuals under the age of 18 should consult a licensed healthcare professional before using any dietary supplement. This content is not a substitute for professional medical consultation, diagnosis, or treatment.
PRICING AND AVAILABILITY DISCLAIMER: Pricing, product availability, promotional offers, and guarantee terms are subject to change without notice. Pricing information in this article reflects publicly available information at the time of writing. Confirm current pricing, availability, and return terms on the official brand website at prohealth.com before making any purchase decision.
PUBLISHER INDEPENDENCE DISCLAIMER: This article was prepared as promotional content by a party with an affiliate relationship to the product discussed. The article does not represent the independent editorial opinion of Accesswire or Newswire.com. The publisher of this content is not responsible for the accuracy of brand-provided product information, changes to product formulations, or the performance of products discussed.
TRADEMARK AND INTELLECTUAL PROPERTY NOTICE: MicrobiomeX® is a registered trademark of BioActor B.V. ButyroGen® is a registered trademark of NutriScience Innovations, LLC. All other brand names and trademarks referenced in this article are the property of their respective owners. Trademark references are made for descriptive purposes only and do not imply endorsement by trademark owners of this content.
REGULATORY STATUS NOTICE: BPC-157 is not approved by the FDA for human therapeutic use. It is classified under WADA's S0 (Unapproved Substances) category and is prohibited in competitive sport regardless of administration route. BPC-157's regulatory status is complex and may vary by use, jurisdiction, and product category, including FDA regulatory and safety concerns regarding certain BPC-157-related bulk substances used in compounding contexts. Regulatory classifications are subject to change; buyers are responsible for verifying current regulatory status in their jurisdiction and applicable testing programs before purchase. The 2026 WADA Prohibited List, in force as of January 1, 2026, is the authoritative source athletes and their support personnel should consult.
SOURCE: ProHealth